PI3K-mTOR in Cancer and Cancer Therapy

Published by: Humana Press Inc  

People

  1. Chandarlapaty
    Chandarlapaty

Groups

  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1)
  2. Breast Medicine Service (1)
  3. Department of Medicine (1)
  4. GSK Faculty (1)
  5. Human Oncology and Pathogenesis Program (1)
  6. Solid Tumor Oncology Division (1)
Search Within
  1. "Book section"
Formats
  1. Book Section (1)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1)
  2. Breast Medicine Service (1)
  3. Department of Medicine (1)
  4. GSK Faculty (1)
  5. Human Oncology and Pathogenesis Program (1)
  6. Solid Tumor Oncology Division (1)
People
  1. Payal Shah (1)
  2. Sarat Chandarlapaty (1)
Years
  1. 2016 (1)
Publishers
  1. Humana Press Inc (1)

Results (1)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Resistance to PI3K pathway inhibition
    Book Section

    Shah, P. D.; Chandarlapaty, S.
    In Dey, N.; De, P.; Leyland-Jones, B. (Eds.) PI3K-mTOR in Cancer and Cancer Therapy (2016)

    Fulltext@MSK | Save

    • PI3K-mTOR in Cancer and Cancer Therapy – authorized name for:

    Name ISSN / ISBN Publisher
    Cancer Drug Discovery and Development 2196-9906 Humana Press Inc
    Cancer Drug Discovery and Development 2196-9906 Humana Press Inc
    Cancer Drug Discovery and Development. Targets for cancer chemotherapy: Transcription factors and other nuclear proteins 0-89603-938-2 Humana Press Inc
    Pi3k-Mtor in Cancer and Cancer Therapy 978-3-319-34209-2 Springer
    Pi3k-Mtor in Cancer and Cancer Therapy 978-3-319-34209-2 Springer
    PI3K-mTOR in Cancer and Cancer Therapy 978-3-319-34209-2 Humana Press Inc
    Resistance to PI3K Pathway Inhibition 978-3-319-34209-2 Springer
    Unknown (2196-9906) 2196-9906 Humana Press Inc